Drug therapy for the cardiac complications of diabetes

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 2, 2004, Pages 195-200

  Connelly, Kim ^a   Kelly, Darren J ^a   Langham, Robyn ^a   Krum, Henry ^b   Gilbert, Richard E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ACARBOSE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALT 486; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; AROMATIC COMPOUND; BENFOTIAMINE; C 39 0028; CALPHOSTIN C; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NNC 39 0028; PENTOXIFYLLINE; PIOGLITAZONE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PYRIDORIN; PYRIDOXAL; PYRIDOXAMINE; PYRIDOXINE; RUBOXISTAURIN; STAUROSPORINE; TENILSETAM; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; FLU LIKE SYNDROME; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DYSFUNCTION; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; RECEPTOR BLOCKING; SYSTOLIC HYPERTENSION; TREATMENT PLANNING; VASCULITIS;

EID: 13344281644     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.09.008     Document Type: Review

References (43)

1. H. Krum R.E. Gilbert Demographics and concomitant disorders in heart failure Lancet 362 2003 147-158
2. J.W. Baynes S.R. Thorpe Role of oxidative stress in diabetic complications: A new perspective on an old paradigm Diabetes 48 1999 1-9
3. M. Bendayan Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes Kidney Int. 54 1998 438-447
4. M. Brownlee Glycation products and the pathogenesis of diabetic complications Diabetes Care 15 1992 1835-1843
5. D.L. Price et al. Chelating activity of advanced glycation end-product inhibitors J. Biol. Chem. 276 2001 48967-48972
6. M. Brownlee et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking Science 232 1986 1629-1632
7. G.R. Norton et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects Am. J. Hypertens. 12 1999 563-571
8. J.R. Rumble et al. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products J. Clin. Invest. 99 1997 1016-1027
9. B.I. Freedman et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II) Control. Clin. Trials 20 1999 493-510
10. M. Kochakian et al. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats Diabetes 45 1996 1694-1700
11. P.S. Oturai et al. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats Metabolism 49 2000 996-1000
12. K. Tsuchida et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195 Diabetologia 42 1999 579-588
13. J.L. Figarola et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats Diabetologia 46 2003 1140-1152
14. T.O. Metz et al. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications Arch. Biochem. Biophys. 419 2003 41-49
15. V.M. Monnier Intervention against the Maillard reaction in vivo Arch. Biochem. Biophys. 419 2003 1-15
16. D.S. Raj et al. Advanced glycation end products: A nephrologist's perspective Am. J. Kidney Dis. 35 2000 365-380
17. H. Vlassara et al. Protein glycation in the kidney - role in diabetes and aging Kidney Int. 49 1996 1795-1804
18. B.I. Hudson et al. Blockade of receptor for advanced glycation endproducts: A new target for therapeutic intervention in diabetic complications and inflammatory disorders Arch. Biochem. Biophys. 419 2003 80-88
19. H.M. Lander et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress J. Biol. Chem. 272 1997 17810-17814
20. H.J. Huttunen et al. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways J. Biol. Chem. 274 1999 19919-19924
21. J.S. Huang et al. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells Biochem. J. 342 1999 231-238
22. A.M. Schmidt D.M. Stern RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes Trends Endocrinol. Metab. 11 2000 368-375
23. S. Vasan et al. Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo Nature 382 1996 275-278
24. B.H. Wolffenbuttel et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes Proc. Natl. Acad. Sci. USA 95 1998 4630-4634
25. D.A. Kass Getting better without AGE: New insights into the diabetic heart Circ. Res. 92 2003 704-706
26. D.A. Kass et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 2001 1464-1470
27. S. Vasan et al. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks Arch. Biochem. Biophys. 419 2003 89-96
28. A.C. Newton Protein kinase C: Structure, function, and regulation J. Biol. Chem. 270 1995 28495-28498
29. M. Murphy et al. Protein kinases C: Potential targets for intervention in diabetic nephropathy Curr. Opin. Nephrol. Hypertens. 7 1998 563-570
30. X. Feng et al. Visualization of dynamic trafficking of a protein kinase C betaII/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitization J. Biol. Chem. 273 1998 10755-10762
31. R.K. Studer et al. Low-density lipoprotein stimulation of mesangial cell fibronectin synthesis: Role of protein kinase C and transforming growth factor-beta J. Lab. Clin. Med. 125 1995 86-95
32. R.K. Studer et al. Thromboxane stimulation of mesangial cell fibronectin synthesis is signalled by protein kinase C and modulated by cGMP Kidney Int. 46 1994 1074-1082
33. H. Wakasaki et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy Proc. Natl. Acad. Sci. USA 94 1997 9320-9325
34. J.C. Braz et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure Nat. Med. 10 2004 248-254
35. P.G. Goekjian Jirousek MR: Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development Curr. Med. Chem. 6 1999 877-903
36. H. Ishii et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor Science 272 1996 728-731
37. D.J. Kelly et al. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension Diabetes 52 2003 512-518
38. J.A. Beckman et al. Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans Circ. Res. 90 2002 107-111
39. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813-820
40. P. Rouet-Benzineb et al. Protein kinase C isoform expression in normal and failing rabbit hearts Circ. Res. 79 1996 153-161
41. J. Wang et al. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction Am. J. Physiol. Heart Circ. Physiol. 284 2003 H2277-H2287
42. T.D. Giles et al. Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat Am. J. Physiol. 274 1998 H295-H307
43. 2+-sensitive isoforms in the failing human heart Circulation 99 1999 384-391